IAG Strengthens Team with New Appointments in the European and North American Offices

IAG Strengthens Team with New Appointments in the European and North American Offices

IAG, Image Analysis Group announced today the expansion of its executive management team in London, UK and Philadelphia, USA offices and welcomed Dr. Boubakeur Belaroussi as Head of Product, Maartje Meijer as Head of Operations, Frank Cerrone as a lead MRI Technologist and Yeda Ford as a Head of Commercial Operations.

Dr. Boubakeur Belaroussi, passionate about improving business processes using data-driven technologies (machine learning, IA, Data Science, Predictive Analytics) joins the IAG’s London office after spending over 12 years in clinical research, handling healthcare projects in information system development in both start-up and global companies. Bouba will lead the team furthering the development of IAG’s proprietary development platform DYNAMIKA and managing complex projects and clinical trial programs, collaborating with cross-functional teams and focusing the teams on our bio-pharmaceutical partners development goals.

Maartje Meijere’s earlier experience at one of the top clinical research organizations will bolster support the IAG global operations team in its phase I to III clinical trials in musculoskeletal, oncology and rare disease therapeutic areas.

Frank Cerrone joins IAG’s new team in Philadelphia, PA, USA where he will be responsible for providing oversight to clinical teams on several different assessment criteria including RAMRIS, PSAMRIS, Immune-Related Response Criteria (irRC), and Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and RANO criteria and advanced quantitatve medtholgies, which we bring to early stage  clinical development programs. Franks  brings over 25 years as an MRI technologist working in clinical research studies in oncology and rheumatology.

Yeda Ford joins IAG as a Head of Commercial Operations to oversee IAG’s bio-partnering program and the team of analysts with the focus on expanding IAG relationships with ambitious biotechnologies companies developing novel treatments to address unmet patient needs.

“Not many jobs offer an opportunity to change people’s lives. We are delighted to welcome Yeda, Frank, Maartje and Bouba who share our passion for IAG’s vision and bio-pharmaceutical focus combined with years of experience in the industry,” says Dr. Olga Kubassova, IAG CEO.

 About IAG

IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com

News
Events